biostudies-literatureUnknown156(11)Ran RShanghai JMT-Bio Technology Co., LtdThis study aimed to assess the efficacy and safety of three dosing regimens of JMT103 in patients with bone metastases from solid tumors. Eligible patients were randomly assigned to receive JMT103 subcutaneously, 120 mg every 4 weeks (Cohort 1), 120 mg every 8 weeks (Cohort 2), or 180 mg every 8 weeks (Cohort 3) for up to 49 weeks. The primary endpoint was change from baseline to Week 13 in creatinine-adjusted urinary N-telopeptide (uNTx/Cr). Two hundred and ninety-five patients were randomized, and 293 received at least one dose of JMT103, of whom 96 were assigned to Cohort 1, 97 were assigned to Cohort 2, and 100 were assigned to Cohort 3. The median (interquartile range) percentage reduction in uNTx/Cr at Week 13 was 80.0% (49.9%, 93.4%) in Cohort 1, 73.0% (34.5%, 94.0%) in Cohort 2, anInternational journal of cancer2178-2187https://www.ebi.ac.uk/biostudies/studies/S-EPMC11970543biostudies-literatureEfficacy and safety of JMT103 in patients with bone metastases from solid tumors: A randomized Phase Ib clinical trial.PMC11970543Ran RLi HYin XLi JSun TYan YWang JYuan JXie HGuo HWu SZhou HZang AXiong HfalseEfficacy and safety of JMT103 in patients with bone metastases from solid tumors: A randomized Phase Ib clinical trial.This study aimed to assess the efficacy and safety of three dosing regimens of JMT103 in patients with bone metastases from solid tumors. Eligible patients were randomly assigned to receive JMT103 subcutaneously, 120 mg every 4 weeks (Cohort 1), 120 mg every 8 weeks (Cohort 2), or 180 mg every 8 weeks (Cohort 3) for up to 49 weeks. The primary endpoint was change from baseline to Week 13 in creatinine-adjusted urinary N-telopeptide (uNTx/Cr). Two hundred and ninety-five patients were randomized, and 293 received at least one dose of JMT103, of whom 96 were assigned to Cohort 1, 97 were assigned to Cohort 2, and 100 were assigned to Cohort 3. The median (interquartile range) percentage reduction in uNTx/Cr at Week 13 was 80.0% (49.9%, 93.4%) in Cohort 1, 73.0% (34.5%, 94.0%) in Cohort 2, an2025-01-01T00:00:00Z2025 Jun2026-07-15T11:02:52.537Z2026-07-03T03:15:36.85ZS-EPMC119705433985366710.1002/ijc.35343